Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating edothelial cell nitric oxide production.
Davis
M E
ME
Harrison
D G
DG
D001161:Arteriosclerosis / Q000378:metabolism / Q000517:prevention & control / Q000628:therapy; D051242:Caveolin 1; D022461:Caveolins / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D019204:GTP-Binding Proteins / Q000378:metabolism; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000378:metabolism; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000378:metabolism*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052250:Nitric Oxide Synthase Type III; D011106:Polyisoprenyl Phosphates / Q000378:metabolism; D012717:Sesquiterpenes; D015398:Signal Transduction / Q000187:drug effects; D013481:Superoxides / Q000378:metabolism
C495540:CAV1 protein, human; D051242:Caveolin 1; D022461:Caveolins; D015853:Cysteine Proteinase Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011106:Polyisoprenyl Phosphates; D012717:Sesquiterpenes; D013481:Superoxides; D009569:Nitric Oxide; C004808:farnesyl pyrophosphate; D002784:Cholesterol; D006903:Hydroxymethylglutaryl CoA Reductases; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D019204:GTP-Binding Proteins; C002963:geranylgeranyl pyrophosphate